http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101070025-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J1-0059 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J1-00 |
| filingDate | 2006-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2011-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2011-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101070025-B1 |
| titleOfInvention | New 17β-hydroxysteroid Dehydrogenase Type I Inhibitors |
| abstract | The present invention relates to novel 3, 15 substituted estrone derivatives, salts thereof, pharmaceutical agents comprising these compounds and compounds that exhibit inhibitory compounds of the 17β-hydroxy steroid dehydrogenase type 1 (17β-HSD1) enzyme. It relates to a manufacturing method of these. Moreover, the present invention provides for the therapeutic use of the novel 3,15 substituted estrone derivatives, in particular the inhibition of steroid hormone dependent diseases or disorders, for example 17β-HSD1 enzyme and / or endogenous 17β-estradiol concentrations. It relates to their use in the treatment or prophylaxis of steroid hormone dependent diseases or disorders requiring a lowering of. Moreover, the present invention provides a selective 17β-hydroxy steroid dehydrogenase type 1 having no binding affinity for the estrogen receptor or only pure antagonistic binding affinity for the treatment and prevention of benign gynecological diseases, in particular endometriosis. It relates to the general use of inhibitors. |
| priorityDate | 2003-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 486.